FullStory Survey Shows the Digital Experience Dominates–Not Just Influences–Summer Travel
Travelers, particularly more affluent ones, complete most of their research and booking online before they…
News
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
Telesis Bio to Present at SynBioBeta 2023
Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery SAN DIEGO,…
Telesis Bio to Present at SynBioBeta 2023
Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery SAN DIEGO,…
AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
Leading Diagnostic Healthcare Company Selects Accomplished Operations Executive to Spearhead Growth of Diagnostic Assays Manufacturing…
AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
Leading Diagnostic Healthcare Company Selects Accomplished Operations Executive to Spearhead Growth of Diagnostic Assays Manufacturing…
Data-Driven Studies: Faster and Smarter Results Delivered via Fusion eClinical Suite – OCT East Coast 2023
TORONTO, May 23, 2023 (GLOBE NEWSWIRE) — Axiom Real-Time Metrics (“Axiom”), the premier provider of…
Data-Driven Studies: Faster and Smarter Results Delivered via Fusion eClinical Suite – OCT East Coast 2023
TORONTO, May 23, 2023 (GLOBE NEWSWIRE) — Axiom Real-Time Metrics (“Axiom”), the premier provider of…
New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction
Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy NeuroStar Depression…
New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction
Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy NeuroStar Depression…
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
– Results from the completed Collaborative Health Research Projects (CHRP) study with McMaster University presented…
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases
– Results from the completed Collaborative Health Research Projects (CHRP) study with McMaster University presented…
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company…
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company…
Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement For Celularity’s Halal-Certified Biomaterial Products
Builds on Celularity’s December 2022 announcement of Halal Certification of its commercial-stage biomaterial products, and…
Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement For Celularity’s Halal-Certified Biomaterial Products
Builds on Celularity’s December 2022 announcement of Halal Certification of its commercial-stage biomaterial products, and…
T2 Biosystems Announces First Quarter 2023 Financial Results
Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic…